ADAR1 Capital Management LLC Purchases Shares of 5,000 BioNTech SE Sponsored ADR $BNTX

Key Points

• ADAR1 Capital Management LLC acquired 5,000 shares of BioNTech SE, worth approximately $455,000, in the first quarter, marking a significant new investment in the biotech firm.
• BioNTech's revenue for the last quarter increased by 102.6% year-over-year, although the company reported a loss of ($1.60) earnings per share, missing consensus estimates.
• Thirteen research analysts have given BioNTech a Buy rating, with a current average price target around $135.80, reflecting positive sentiment despite recent earnings challenges.

ADAR1 Capital Management LLC purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,000 shares of the company's stock, valued at approximately $455,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC acquired a new position in BioNTech during the first quarter worth $288,000. GAMMA Investing LLC raised its holdings in BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after purchasing an additional 52,711 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in BioNTech during the fourth quarter worth $238,000. Allianz Asset Management GmbH raised its holdings in BioNTech by 44.3% during the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock worth $10,989,000 after purchasing an additional 37,075 shares during the last quarter. Finally, Cerity Partners LLC acquired a new position in BioNTech during the first quarter worth $357,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reduced their price objective on BioNTech from $138.00 to $136.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Morgan Stanley lifted their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Truist Financial reissued a "buy" rating and issued a $155.00 price target (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, JPMorgan Chase & Co. cut their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, BioNTech has an average rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Trading Up 8.7%

BioNTech stock traded up $8.96 during trading on Friday, hitting $112.46. The company's stock had a trading volume of 2,052,527 shares, compared to its average volume of 669,941. The stock has a market capitalization of $27.04 billion, a price-to-earnings ratio of -70.29 and a beta of 1.39. The stock's fifty day moving average is $109.49 and its 200 day moving average is $104.53. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.